PanGenomic Health Inc - Vancouver, Canada-based precision health company - Pretax loss for the half-year to June 30 widens 20% to CAD2.0 million from CAD1.6 million a year prior, with both figures being the same for expenses of their respective half-years. Company highlights that it introduced in-clinic access to patient vitamin D assessments through the biomarker platform by its subsidiary MUJN Diagnostics Inc. Further, PanGenomic launched an e-commerce platform to market its proprietary natural herbal remedy information library.

Current stock price: CAD0.030

12-month change: down 86%

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.